Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy
PurposeImmunoglobulin (Ig) replacement therapy is an important life-saving treatment modality for patients with primary antibody immune deficiency disorders (PAD). IVIG and SCIg are suitable alternatives to treat patients with PAD but vary in key ways. Existing evidence on patient preferences for Ig...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.827305/full |
| _version_ | 1819275645794910208 |
|---|---|
| author | Juan Marcos Gonzalez Mark Ballow Mark Ballow Angelyn Fairchild Michael Chris Runken |
| author_facet | Juan Marcos Gonzalez Mark Ballow Mark Ballow Angelyn Fairchild Michael Chris Runken |
| author_sort | Juan Marcos Gonzalez |
| collection | DOAJ |
| description | PurposeImmunoglobulin (Ig) replacement therapy is an important life-saving treatment modality for patients with primary antibody immune deficiency disorders (PAD). IVIG and SCIg are suitable alternatives to treat patients with PAD but vary in key ways. Existing evidence on patient preferences for Ig treatments given the complexities associated with IVIG and SCIg treatment is limited and fails to account for variations in preferences across patients. For this reason, we sought to evaluate PAD patient preferences for features of IVIG and SCIg across different patient characteristics.Materials and Methods119 PAD patients completed a discrete-choice experiment (DCE) survey. The DCE asked respondents to make choices between carefully constructed treatment alternatives described in terms of generic treatment features. Choices from the DCE were analyzed to determine the relative influence of attribute changes on treatment preferences. We used subgroup analysis to evaluate systematic variations in preferences by patients’ age, gender, time since diagnosis, and treatment experience.ResultsPatients were primarily concerned about the duration of treatment side effects, but preferences were heterogeneous. This was particularly true around administration features. Time since diagnosis was associated with an increase in patients’ concerns with the number of needles required per infusion. Also, patients appear to prefer the kind of therapy they are currently using which could be the result of properly aligned patient preferences or evidence of patient adaptive behavior.ConclusionsHeterogeneity in preferences for Ig replacement treatments suggests that a formal shared decision making process could have an important role in improving patient care. |
| first_indexed | 2024-12-23T23:27:37Z |
| format | Article |
| id | doaj.art-3bce66c006df4d2a9fc6d56f5437ff5b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-23T23:27:37Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3bce66c006df4d2a9fc6d56f5437ff5b2022-12-21T17:26:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-02-011310.3389/fimmu.2022.827305827305Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin TherapyJuan Marcos Gonzalez0Mark Ballow1Mark Ballow2Angelyn Fairchild3Michael Chris Runken4Department of Population Health Sciences, Duke University, Durham, NC, United StatesDivision of Allergy & Immunology, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, United StatesJohns Hopkins All Children’s Hospital, Saint Petersburg, FL, United StatesKenan-Flagler Business School, University of North Carolina at Chapel Hill, Chapel Hill, NC, United StatesScientific & Medical Affairs, Global Health Economics and Outcomes Research, Grifols SSNA, Durham, NC, United StatesPurposeImmunoglobulin (Ig) replacement therapy is an important life-saving treatment modality for patients with primary antibody immune deficiency disorders (PAD). IVIG and SCIg are suitable alternatives to treat patients with PAD but vary in key ways. Existing evidence on patient preferences for Ig treatments given the complexities associated with IVIG and SCIg treatment is limited and fails to account for variations in preferences across patients. For this reason, we sought to evaluate PAD patient preferences for features of IVIG and SCIg across different patient characteristics.Materials and Methods119 PAD patients completed a discrete-choice experiment (DCE) survey. The DCE asked respondents to make choices between carefully constructed treatment alternatives described in terms of generic treatment features. Choices from the DCE were analyzed to determine the relative influence of attribute changes on treatment preferences. We used subgroup analysis to evaluate systematic variations in preferences by patients’ age, gender, time since diagnosis, and treatment experience.ResultsPatients were primarily concerned about the duration of treatment side effects, but preferences were heterogeneous. This was particularly true around administration features. Time since diagnosis was associated with an increase in patients’ concerns with the number of needles required per infusion. Also, patients appear to prefer the kind of therapy they are currently using which could be the result of properly aligned patient preferences or evidence of patient adaptive behavior.ConclusionsHeterogeneity in preferences for Ig replacement treatments suggests that a formal shared decision making process could have an important role in improving patient care.https://www.frontiersin.org/articles/10.3389/fimmu.2022.827305/fullprimary immune deficiency disordersimmunoglobulin replacement therapyIVIgSCIGpatient preferencesdiscrete-choice experiment |
| spellingShingle | Juan Marcos Gonzalez Mark Ballow Mark Ballow Angelyn Fairchild Michael Chris Runken Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy Frontiers in Immunology primary immune deficiency disorders immunoglobulin replacement therapy IVIg SCIG patient preferences discrete-choice experiment |
| title | Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy |
| title_full | Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy |
| title_fullStr | Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy |
| title_full_unstemmed | Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy |
| title_short | Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy |
| title_sort | primary immune deficiency patients preferences for replacement immunoglobulin therapy |
| topic | primary immune deficiency disorders immunoglobulin replacement therapy IVIg SCIG patient preferences discrete-choice experiment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.827305/full |
| work_keys_str_mv | AT juanmarcosgonzalez primaryimmunedeficiencypatientspreferencesforreplacementimmunoglobulintherapy AT markballow primaryimmunedeficiencypatientspreferencesforreplacementimmunoglobulintherapy AT markballow primaryimmunedeficiencypatientspreferencesforreplacementimmunoglobulintherapy AT angelynfairchild primaryimmunedeficiencypatientspreferencesforreplacementimmunoglobulintherapy AT michaelchrisrunken primaryimmunedeficiencypatientspreferencesforreplacementimmunoglobulintherapy |